Fully Human Antibody Discovery Antibodies have emerged as significant therapeutics in the market. Accelerating antibody discovery is essential in the fight to develop first-in-class drugs or treatments for new pandemic pathogens, such as coronavirus. Fully human antibody discovery is widely used in early antibody leads discovery. In this webinar, we compare how scientists use innate immune systems to develop phage displayed libraries, Ab humanized animals, and single B cell technology. Recommended strategies for human antibody discovery will also be discussed. Speaker: Dr. Yikai Qiu, Senior Scientist, ProBio Date: Apr. 3rd, 2020 Time: 11:00-11:40AM EST Register Anti-idiotype antibody generation and applications in antibody drug discovery Anti-idiotypic Antibody Service DNA Immunization Service Therapeutic Hybridoma Development High specificity & affinity Fast turnaround time: 2-3 months. 100% success rate Solution to problematic antigens, such as membrane proteins Proven track record with 100% success rate Full spectrum of immunization approaches One stop solution High throughput screening « Previous Page ProBio Announces New Executive Appointments Next Page ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy » Contact us Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188 Fax: 1-732-210-0262
Latest WebinarsNavigating Biologics Challenges:Regulatory, Process Development, and Tech Transfer SolutionsPre-clinical DMPK Study and Generation of Toolbox to Facilitate PK/ADA AnalysisMultiple Solutions of Functional Leads Discovery and EngineeringAntibody Engineering and Developablity ServiceFind More Therapeutic Antibody Categories